drugset
drugset / Trial / NCT00547560

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population

NCT00547560 ↗

Phase 1 Completed 49 enrolled Wyeth is now a wholly owned subsidiary of Pfizer Pfizer · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.

Timeline

Start
2007-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Begacestat Small molecule 10 mg Oral
Subject Begacestat Small molecule 50 mg Oral

Indications

No indication recorded.